Eastham JA et al., 2022: The joint AUA/ASTRO/SUO guideline on clinically localized prostate cancer covers risk assessment, active surveillance, surgery, radiation and follow-up; across all 46 pages it contains no recommendation for chemotherapy, and the words 'chemotherapy' and 'docetaxel' do not appear.
The target population was patients with clinically localized prostate cancer, defined as up to clinical stage T3 (by digital rectal examination [DRE]) prostate cancer without nodal or distant metastasis (N0M0) on conventional imaging.
1
Eastham JA et al., 2022: The joint AUA/ASTRO/SUO guideline on clinically localized prostate cancer covers risk assessment, active surveillance, surgery, radiation and follow-up; across all 46 pages it contains no recommendation for chemotherapy, and the words 'chemotherapy' and 'docetaxel' do not appear. Funder: American Urological Association Education and Research Inc. Conflicts: AUA panel disclosures published separately, not in this PDF. Maker: n/a. Comparator: n/a. Correction: the prompt calls this the 'AUA/ASTRO/SUO' guideline; the document itself titles it 'AUA/ASTRO Guideline 2022, Endorsed by SUO'. Full-text search returns 0 hits for 'docetaxel' and 0 for 'chemo'.
